The pharmacologic impact of FGF21 on obese and inflamed adipose tissues, residential adipocytes, and the associated metabolic abnormalities and inflammatory damage in the context of obesity is expected to be more direct and significant than some of the known metabolic and inflammatory regulators, such as leptin, adiponectin, and IL6. This evidence concerns the gene LEP and obesity disorder.